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2838Objective: The aim of our study was to evaluate the early outcomes and 1-year survival of patients undergoing
minimally invasive aortic valve replacement with the Perceval S sutureless valve for severe aortic stenosis.
Methods: From March 2010 to March 2013, 281 high-risk patients underwent minimally invasive aortic valve
replacement with the Perceval S sutureless valve through either right anterior minithoracotomy (n ¼ 164) or
upper ministernotomy (n ¼ 117) at 2 cardiac centers.
Results: The overall in-hospital mortality was 0.7% (2 patients). The overall median cardiopulmonary bypass
and crossclamp time was 81 minutes (interquartile range, 68-98) and 48 minutes (interquartile range, 37-60),
respectively. Postoperative stroke occurred in 5 patients (1.8%). The incidence of paravalvular leak greater
than 1 of 4 and atrioventricular block requiring pacemaker implantation was 1.8% (5 patients) and 4.2%
(12 patients), respectively. No migration occurred, and the mean postoperative gradient was 13  4 mm Hg.
At a median follow-up of 8 months (interquartile range, 4-14), the overall survival was 90%.
Conclusions: Minimally invasive aortic valve replacement with the Perceval S sutureless valve in high-risk
patients is a safe and reproducible procedure associated with excellent hemodynamic results, postoperative
outcomes, and 1-year survival. (J Thorac Cardiovasc Surg 2014;148:2838-43)See related commentary on pages 2843-4.The clinical outcomes after elective isolated aortic valve
replacement (AVR) have significantly improved in previous
years.1 According to the recent Fourth European Associa-
tion for Cardio-Thoracic Surgery adult cardiac surgery
database report, the overall operative mortality has ranged
from 1.2 to 14%, depending on patient age and overall
risk profile.2 Despite these results, less invasive procedures
have been developed as an alternative to the conventional
technique to reduce the surgical trauma and preserve the
same quality, safety, and efficacy of the full sternotomy
approach.3 Minimally invasive AVR (MIAVR) has shown
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The Journal of Thoracic and Cardiovascular Sursatisfaction, providing less pain, faster recovery, and a
shorter hospital stay.4-7 However, traditionalists have
claimed that MIAVR is technically more complex,
requires a distinct learning curve, and that the only clear
benefit to the patient is cosmesis.8,9 Furthermore, the
longer crossclamp and cardiopulmonary bypass (CPB)
times associated with the MIAVR approach have raised
some concerns regarding its safety in elderly and high-risk
patients, because they are well-known risk factors for
adverse outcomes after cardiac surgery.10,11 In this setting,
the implantation of sutureless valves might facilitate the
MIAVR approach, reducing the operative times.
The Perceval S sutureless valve (Sorin Biomedica Cardio
Srl, Salluggia, Italy) is a new self-expanding prosthesis
made of bovine pericardium mounted in a nitinol stent,
designed as an alternative to the traditional prostheses to
simplify surgical implantation. Recently, the Perceval S
has shown excellent results in term of postoperative
outcomes and hemodynamic performance, decreasing the
operative times.12-15 The aim of our study was to evaluate
the early outcomes and 1-year survival of patients who had
undergone MIAVR for severe aortic valve stenosis with
the Perceval S sutureless valve at 2 different institutions.METHODS
Patient Selection and Data Collection
A retrospective, observational study was undertaken of prospectively
collected data from consecutive patients with severe aortic stenosisgery c December 2014
Abbreviations and Acronyms
AVR ¼ aortic valve replacement
CPB ¼ cardiopulmonary bypass
L ¼ large
M ¼ medium
MIAVR ¼ minimally invasive AVR
MS ¼ ministernotomy
PVL ¼ paravalvular leakage
RT ¼ right anterior minithoracotomy
S ¼ small
STS ¼ Society of Thoracic Surgeons
TAVI ¼ transcatheter aortic valve implantation
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D(mean gradient>40 mm Hg or an aortic valve area<1 cm2) undergoing
MIAVR from March 2010 to March 2013. The completed data collection
forms were entered in a local databases and included several sections
completed by the anesthetists, cardiac surgeons, and perfusionists involved
in the care of the patients. A total of 281 consecutive patients with severe
aortic stenosis underwent MIAVR with the Perceval S sutureless valve at 2
European cardiac centers (Fondazione Toscana G. Monsaterio, Massa,
Italy; and Klinikum N€urnberg, N€urnberg, Germany). Of the 281 patients,
164 underwent right anterior minithoracotomy (RT) and 117 underwent
a ministernotomy (MS) approach. The local committee of institutional
review boards approved the study to meet ethical and legal requirements,
and individual patient consent was waived.
The selection criteria for the Perceval S sutureless valvewere severe calci-
fied aortic valve stenosis, or steno-insufficiency, age65 years, EuroSCORE
I>5%, and a small calcified aortic root and/or annulus. The exclusion criteria
for valve implantation were acute endocarditis, bicuspid aortic valve replace-
ment with asymmetric sinus of Valsalva, dilatation of the ascending aorta>4
cm in the sinotubular junction, and a ratio between the diameter of the sinus of
Valsalva and diameter of the superior annulus>1.3 (a ratio>1.3 can prevent
correct fixation of the valve stent on the aorta). Mortality was defined as any
death occurring within 30 days of surgery. Postoperative stroke was diag-
nosed if evidence was found of a new neurologic deficit with morphologic
substrate confirmed by computed tomography or nuclear magnetic resonance
imaging. Before discharge, all patients underwent transthoracic echocardiog-
raphy. The grade of paravalvular leakage (PVL) regurgitationwas determined
from the color Doppler imaging findings and classified into 4 grades: trivial, 1
of 4; mild, 2 of 4; moderate, 3 of 4; and severe, 4 of 4. The follow-up data
were 100% complete.
Preoperative Planning and Surgical Procedures
All patients undergoing MIAVR underwent an accurate preoperative
transthoracic echocardiographic study for a better evaluation of the aortic
valve, aortic annulus diameter, and symmetry of the Valsalva sinuses.
Patients who were a candidate for a RT approach underwent 64-slice
thoracic computed tomography without contrast enhancement to evaluate
the relationship among the aortic valve, sternum, and intercostal spaces.
The patients were considered suitable for a RT approach if, at the level
of the main pulmonary artery, the ascending aorta was rightward with
respect to the right sternal border and the distance from the ascending aorta
to the sternum did not exceed 10 cm. The MS and RT approaches were
chosen according to center preferences. Specifically, MS was the main
approach in Nuremberg (95%), and RT was mainly performed in Massa
(90%, with the remaining not suitable for RT for anatomic reasons).
The surgical techniques have been previously reported.16-18 In brief, RT
was performed through a 5- to 7-cm skin incision placed at the level of the
second intercostal space. Direct aortic cannulation was performed usingThe Journal of Thoracic and Carflexible cannulas, such as Easyflow (Sorin, Sallugia, Italy), and venous
drainagewas achieved with a Bio-MedicusMultistage cannula (Medtronic,
Minneapolis, Minn) or remote access perfusion cannula (Sorin) and
inserted through the femoral vein into the right atrium, and the correct po-
sition was reached using the Seldinger technique under transesophageal
echocardiographic guidance.16 TheMS sternotomy approach was achieved
through a 6- to 10-cm midline vertical skin incision, performing a partial J
sternotomy at the third to fifth intercostal space or a V-shaped ministerno-
tomy at the level of the second intercostal space.17,18 After CPB had been
established, a left ventricular vent was placed through the right superior
pulmonary vein, and the patients were cooled to 34C. The ascending
aorta was clamped with the DeBakey crossclamp or with the Glauber
clamp (Cardiomedical GmbH, Langenhagen, Germany, distributed by
Sorin), and antegrade cardioplegic solution was given into the aortic root
or selectively into the coronary ostia using warm blood cardioplegia. In
all cases, the surgical field was flooded with carbon dioxide until closure
of the aortotomy.
Perceval S Implantation
The transverse aortotomywasperformedapproximately 1.5 to 2 cmhigher
than ordinary aortotomy forAVR.The reference pointwas the inferiormargin
of the Concato preaortic bundle. The diseased native valve was completely
removed and the aortic annulus thoroughly decalcified and sized. The valve
sizer was designed so that the intra-annular head of the sizer (yellow) has
the same external diameter as the supra-annular head (white) of the smaller
size. For the appropriate sizing, the native annulus should allow the passage
of the intra-annular head but not the supra-annular head of the same sizer
(eg, intra-annular head of size large [L] should correspond to the supra-
annular head of size medium [M]). Afterward, 3 guiding 4-0 Prolene sutures
were placed at the nadir point of each valve sinuses to act as a reference for
accurate alignment of the inflow portion of the prosthesis into the aortic
annulus. The valve was collapsed using a specific device system and con-
nected to the guiding sutures through 3 bottom holes placed on the midpart
of the inflowring.Thedeployment systemwasparachuteddown into the aortic
root and the valve released into the aortic annulus. The inflow ring should
completely cover the aortic annulus, such that no part of the native aortic
annulus is exposed. Although not recommended by Sorin, it is still possible
to adjust the valve position using the forceps. Once coaptation of the 3 leaflets
had been checked, a balloon was inserted into the sutureless valve and
expanded with warm saline solution for 30 seconds at a pressure of 4 mBar.
Finally, the 3 guiding sutures were removed; the valve was again checked
for the correct position, and the aortotomywas closedusing 4-0or 5-0 running
sutures. The patient was weaned from CPB, and the valve was evaluated for
the presence of PVL using transesophageal echocardiography.
Currently, 3 sizes are available: small (S) (21 mm), M (23 mm), and
L (25 mm). The extra large (XL) size is still under investigation
in a multicenter study for the European Commission (‘‘Conformite
Europeene’’) approval and was used exclusively by the Nuremberg group.
Statistical Analysis
Continuous data are presented as themean standard deviation ormedian
and interquartile range (IQR) and categorical data as percentages. The
Kolmogorov-Smirnov test was used to check for normality of the
postoperative gradients before additional analysis. Differences between
mean postoperative gradients and valve sizes were tested using the Kruskal-
Wallis test. Kaplan-Meier estimates were used to determine total survival
and event-free survival (defined as the absence of reoperation, endocarditis,
stroke, and death). Statistical analysis was performed using the Statistical
Package for Social Sciences, version 15.0 (SPSS, Chicago, Ill).
RESULTS
The baseline and intraoperative characteristics are
reported in Tables 1 and 2. All valves were successfullydiovascular Surgery c Volume 148, Number 6 2839
TABLE 1. Preoperative patient characteristics (n ¼ 281)
Characteristic Value
Age (y) 76.8  6
Female gender 174 (61.9)
Diabetes 62 (22.1)
Chronic pulmonary disease 45 (16)
Hypertension 238 (84.7)
NYHA III-IV 134 (47.7)
Extracardiac arterioplasty 33 (11.7)
Previous cardiac operations 5 (1.8)
Preoperative EF (%) 56.8  8.5
Poor EF (<30%) 7 (2.5)
Chronic renal dysfunction (SCr>2 mg/dL) 11 (3.9)
Pulmonary hypertension 37 (13.2)
Logistic EuroSCORE 8 (5-12)
RT approach 164 (58.4)
MS approach 117 (41.6)
Data presented as mean standard deviation, n (%), or median (interquartile range).
NYHA, New York Heart Association; EF, ejection fraction; SCr, serum creatinine;
RT, right anterior minithoracotomy; MS, ministernotomy.
TABLE 3. Postoperative outcomes (n ¼ 281)
Outcomes Value
Mortality 2 (0.7)
Stroke 5 (1.8)
Re-exploration for bleeding 8 (2.8)
Conversion to sternotomy 4 (1.4)
AV block requiring PMK 12 (4.2)
PVL>1 of 4 5 (1.8)
ICU stay (d) 1 (1-2)
Ward stay (d) 8 (6-10)
Data presented as n (%) or median (interquartile range). AV, Atrioventricular;
PMK, pacemaker; ICU, intensive care unit; PVL, paravalvular leakage.
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Dimplanted using either RT or MS. The median CPB and
crossclamp time was 81 minutes (IQR, 68-98) and 48
minutes (IQR, 37-60), respectively. In the RT group, the
CPB and crossclamp time was 74 minutes (IQR 87-107)
and 55 minutes (IQR 47-65), respectively. In the MS
group, the CPB and crossclamp time was 72 minutes
(IQR 58-89) and 37 minutes (IQR 30-46; Table 2). The
most common size used in both approaches was size L
(n ¼ 141, 50.2%). Of the patients, 34 (12.1%) received
size S and 97 (34.5%) size M. The XL size was implanted
in 9 patients (3.2%) through the MS approach in
Nuremberg as a part of the multicenter study for the
European Commission approval.
Overall, in-hospital mortality was 0.7% (1 patient died of
multiorgan failure and 1 of liver insufficiency), with a
predicted median EuroSCORE of 8% (IQR, 5%-12%).
The outcomes are reported in Table 3. Four patients
(1.4%) required conversion to full sternotomy because of
bleeding. No valve migration was reported. In 5 patients,
owing to incorrect alignment of the prosthesis into the
aortic annulus, the valve was explanted, recollapsed, and
reimplanted with success. Two patients required betterTABLE 2. Intraoperative characteristics
Characteristic MIAVR (n ¼ 281) RT (n ¼ 164) MS (n ¼ 117)
CPB time (min) 81 (68-98) 74 (87-107) 72 (58-89)
Crossclamp time (min) 48 (37-60) 55 (47-65) 37 (30-46)
Perceval S size
S (21 mm) 34 (12.1) 21 (12.8) 13 (11.1)
M (23 mm) 97 (34.5) 57 (34.8) 40 (34.2)
L (25 mm) 141 (50.2) 86 (52.4) 55 (47)
XL (27 mm) 9 (3.2) 0 9 (7.7)
Data presented as median (interquartile range) or n (%).MIAVR, Minimally invasive
aortic valve replacement; RT, right anterior minithoracotomy; MS, ministernotomy;
CPB, cardiopulmonary bypass; S, small; M, medium; L, large; XL, extra large.
2840 The Journal of Thoracic and Cardiovascular Surannulus decalcification. These complications occurred in
the first phase of our study, suggesting a possible learning
curve effect. Postoperative stroke occurred in 5 patients
(1.8%). Twelve patients (6%) had trivial (1 of 4) PVL.
The incidence of PVL >1 of 4 was 1.8% (5 patients);
4 patients (1.4%) had mild (2 of 4) PVL, with 2 diagnosed
at discharge and 2 in the operating room. One patient
(0.3%) had mild (2 of 4) PVL in the operating room that
had become moderate (3 of 4) at discharge. In these
patients, we chose to leave the PVL owing to the patients’
age and comorbidities. The incidence of atrioventricular
block requiring pacemaker implantation was 4.2%
(12 patients). At discharge, the mean and peak post-
operative gradient was 13  4 and 24  8 mm Hg,
respectively. No difference was found between the valve
size and the mean gradient. The mean postoperative
gradient for each size was 13.5  5.1 mm Hg for size S,
13.7  4.5 mm Hg for size M, 12.8  4 mm Hg for size
L, and 13.5  3.2 mm Hg for size XL (P ¼ .36).
At a median follow-up of 8 months (IQR, 4-14), the
1-year survival was 90% (Figure 1). Overall, the
event-free survival was 82%. Finally, 1 patient required
reoperation for endocarditis caused by Aspergillus spp,
and the freedom from reoperation or endocarditis was
99.6%.DISCUSSION
Our study has shown that minimally invasive aortic valve
procedures using the Perceval S sutureless valve with an RT
or MS approach is a safe procedure associated with a low
incidence of mortality and postoperative complications.
Despite the increased risk profile and advanced age of our
patients, the in-hospital mortality was 0.7%, lower than
the recent mortality rate reported in The Society of
Thoracic Surgeons (STS) and European Association for
Cardio-Thoracic Surgery adult cardiac surgery database.
Moreover, the low incidence of PVL and permanent
pacemaker implantation and the short operative times
have confirmed the safety and feasibility of this valve in
minimally invasive approaches, making this access
technically easier and more reproducible. Finally, we havegery c December 2014
FIGURE 1. Graph showing cumulative survival.
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regardless of the prosthesis size. Compared with standard
AVR, MIAVR has shown excellent outcomes in terms of
postoperative complications and hospital stay,4,5
suggesting it might be of benefit particularly in older and
fragile patients.3-6 Despite these results, controversies
exist regarding the minimally invasive approach, because
several prospective randomized trials have failed to
demonstrate any theoretical advantage.4 Furthermore, it
has been shown that MIAVR is associated with a longer
CPB and aortic crossclamp times compared with traditional
surgery.4,5 The reduction in working space for the exposure
and implantation of the prosthetic valves is more complex
and technically challenging (especially in small aortic
annuli), reflecting the longer operative times and the slow
learning curve. That has raised some concerns regarding
its safety in high-risk patients, because the longer CPB
and crossclamp times might eliminate the benefits offered
by the minimally invasive approach.8,9 Recently, we have
described a low rate of complication after MS or RT;
however, we have confirmed the longer operative times
compared with the full sternotomy.7,19 The drawback of
the increasing surgical times could be avoided by the
adoption of sutureless technology, which might facilitate
the MIAVR approach.
As an alternative to the biologic stented valve, the
Perceval S sutureless valve was designed to avoid passing
the stitches through the annulus and suture knotting to
minimize the surgical trauma to the aortic annulus and,
consequently, reduce the ischemic time. To date, several
trials have demonstrated excellent clinical and hemo-
dynamic outcomes for patients undergoing AVR with theThe Journal of Thoracic and CarPerceval S.12-15 However, these studies had focused
mainly on full sternotomy. Few studies have focused on a
minimally invasive approach.15,17,20 In a series of 32
high-risk patients, Flameng and colleagues12 implanted
Perceval S valves within 20minutes of aortic crossclamping
and reported no operative mortality and excellent clinical
and hemodynamic outcomes. However, only 1 patient had
undergone a partial upper ministernotomy. In a larger study,
Folliguet and colleagues13 reported presented the outcomes
of 208 high-risk patients undergoing AVR. The mean
crossclamp time for isolated AVR was 33 minutes, with
an overall in-hospital mortality of 2.4%. Survival at 12
months was 87%, and freedom from reoperation was
96%. Although the investigators had concluded that the
Perceval S can be easily implanted using MIAVR, only
22% of the patients (n ¼ 45) had undergone a mini-AVR
approach.13 Nevertheless, no clinical outcomes associated
with MIAVR were reported. Finally, Santarpino and
colleagues14 confirmed these results, including 51 patients
who had undergone J ministernotomy. In contrast, Shrestha
and colleagues15 described the outcomes of 35 patients who
had undergone ministernotomy and concluded that the
Perceval S sutureless valve is a technically more reproduc-
ible alternative for mini-AVR, even in small and calcified
aortic roots. To the best of our knowledge, our study is
the largest reporting the outcomes of patients undergoing
MIAVR. The strength of our report was that we have
described the postoperative results of the 2 most common
minimally invasive approaches. The in-hospital mortality
was 0.7%, and, despite their high-risk profile and advanced
age, the morbidity was low, and all the patients recovered
well from the surgery. Moreover, compared with our
previous studies of MIAVR with stented valves, we found
a 38% and 40% reduction in the crossclamp and CPB
time in the RT group and 43% and 35% in the MS group,
confirming that sutureless valves can facilitate the surgical
procedure, respectively. Specifically, the mean crossclamp
and CPB time for RT and MS using stented valves was
89  32 and 123  45 minutes in the RT group and
66  20 and 105  35 minutes in the MS group.16,21 We
recognize that our operative times were still longer than
those reported by other Perceval studies; however, those
studies focused mainly on median standard sternotomy or
reported a low percentage of patients undergoing MIAVR.
Furthermore, the STS national database reported that the
mean crossclamp and CPB time for isolated AVR with
full sternotomy was 78 and 106 minutes, respectively
(available at: www.sts.org/documents/pdf/Spring2005STS
ExecutiveSummary.pdf).
Only 1 patient required reoperation after 6 months for
endocarditis. Because the aortic root was intact, we decided
to implant a new Perceval S using an RT approach. Finally,
the 1-year survival was 90%, in line with the recent data
reported by the STS database.22 Because of our outstandingdiovascular Surgery c Volume 148, Number 6 2841
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approach associated with sutureless valves might be
considered an alternative procedure to transcatheter
aortic valve implantation (TAVI) procedures for high-risk
patients. Compared with surgery, transcatheter implantation
has shown similar results in terms of mortality but with an
increased risk of PVL and stroke.23 Although TAVI
represents the real MIAVR because it is performed without
CPB, the main limitation of TAVI is that the native stenotic
valve is left in place, resulting in a high degree of stroke,
PVL, and atrioventricular block. The surgery has the
advantage of removing the diseased valve, resulting in a
lower incidence of PVL and stroke.23,24 It has been shown
that PVL has a negative effect on survival.23 In our
experience, the incidence of postoperative PVL>1 of was
1.8%, much lower than that for those undergoing TAVI
(12.2%).23 Furthermore, this rate was even lower than
that from other Perceval S reports (4%-15%).12-15 In this
regard, the Sorin company has recommended removing
only eccentric and bulky intra-annular calcifications. In
contrast, we strongly believe that accurate and complete
decalcification of the aortic annulus will further reduce
the incidence of paravalvular aortic regurgitation. Finally,
in our series, the rate of postoperative stroke was similar
to that reported by the STS database, confirming the safety
of this valve compared with other valves.1
Finally, an economic comment should be made.
A cost-utility analysis of TAVI in Belgium concluded that
it is not recommended to reimburse for TAVI for high-risk
patients because the patients had no survival benefit after
1 year, the risk of stroke was double, and the costs were
significantly higher.25 In contrast, an economic model has
shown that compared with stented valves the use of the
Perceval S valve might be associated with fewer complica-
tions and with savings, mainly related to a reduction in the
surgery costs and intensive care unit and hospital bed
days.26 Although these valves are more expensive, the
combination of MIAVR and sutureless technology might
minimize the risk of postoperative complications and,
therefore, reduce hospital costs. A well-designed study is
required to evaluate the cost/benefit of TAVI procedures
versus MIAVR using sutureless valves. Also, prospective
randomized trials are required to confirm our suppositions.
Study Limitations
Our study was a retrospective analysis of 2 institutional,
observational, prospectively collected databases. Our study
included patients undergoing 2 different approaches that
cannot be directly comparable, because RT requires
some anatomic conditions that are not required for MS.
Moreover, RT was mainly performed in Massa and MS in
Nuremberg. Although surprising, we found similar
gradients among the valve sizes at discharge. According
to the recommendations of the American Society of2842 The Journal of Thoracic and Cardiovascular SurEchocardiography, the blood velocity across a prosthetic
valve will be dependent on several factors, including the
valve size and type and flow. The flow rate will be
determined by the cardiac output, ventricular function,
viscosity, left ventricular outflow, and body surface area.
These factors could have affected the mean gradients across
the valves.27 However, our database did not include this
information, and the lack of these data did not allow us to
study this topic in depth. Furthermore, no data were
available regarding the gradients during the follow-up
period. A well-designed prospective study is required to
evaluate the potential differences between the 2 minimally
invasive approaches and the Perceval S hemodynamic
performances.
CONCLUSIONS
MIAVR with the Perceval S sutureless valve is a safe
and reproducible procedure associated with excellent
hemodynamic results, postoperative outcomes, and 1-year
survival. Because of these outstanding results, we believe
that MIAVR with sutureless valves could be the real
alternative to the TAVI procedure for high-risk patients.
Prospective randomized trials are required to confirm our
hypothesis.
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DMinimally invasive Perceval S implantation: Does this fill a sizable niche
between sutured and transcatheter aortic valve replacement?Michael O. Kayatta, MD, Hanna A. Jensen, MD, PhD, and Vinod H. Thourani, MDIn this issue of the Journal, Miceli and colleagues1 present
a well-written article on their early experience with place-
ment of the sutureless Perceval S (Sorin SpA, Milan, Italy)
valve through minimally invasive surgical approaches of
either partial sternotomy or right anterior thoracotomy.
Of all patients coming to their centers for isolated aortic
valve replacement (AVR), 40% (n ¼ 281) were found
eligible for these techniques. These patients were elderly
(mean age, 76 years) but on average were a relatively
healthy intermediate-risk population. In-hospital outcomes
were excellent, with very low mortality and only 1.8%
of patients having greater than trace paravalvular leak.
This rate of leaks is extremely low, and has not been
seen by other groups.2,3 Overall, the new postoperative
pacemaker rate was only 4.2%. These results are to be
commended and it is to be hoped will be reproduciblediovascular Surgery c Volume 148, Number 6 2843
